Market Indices
Sector Heatmap
DRUG — Bright Minds Biosciences Inc. Common Stock
NasdaqBright Minds Biosciences Inc. Common Stock
- O
- 49.61
- H
- 51.04
- L
- 48.75
- V
- 154.69K
DRUG — Latest News & Headlines
20 StoriesThe Best Healthcare Stocks to Buy - morningstar.com
The Best Healthcare Stocks to Buy morningstar.com
Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals - CNBC
Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals CNBC
Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3 - Fierce Biotech
Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3 Fierce Biotech
Iovance Stock Surges as Strong Melanoma Drug Demand Drives Growth - Barron's
Iovance Stock Surges as Strong Melanoma Drug Demand Drives Growth Barron's
Kodiak Sciences Up 150% At Opening Bell After Drugs Pass Key Trial - Forbes
Kodiak Sciences Up 150% At Opening Bell After Drugs Pass Key Trial Forbes
AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026? - Yahoo Finance
AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026? Yahoo Finance
Viking Therapeutics Skyrockets On Obesity Drug Data. Lilly Rises, But Novo Falls. - Investor's Business Daily
Viking Therapeutics Skyrockets On Obesity Drug Data. Lilly Rises, But Novo Falls. Investor's Business Daily
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? The Motley Fool
Best Pharmaceutical Stocks to Buy for October 2026 - Zacks Investment Research
Best Pharmaceutical Stocks to Buy for October 2026 Zacks Investment Research
Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s strategy - MarketWatch
Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s strategy MarketWatch
UniQure Insists Huntington’s Drug Is Still on Track as Stock Plunges 36% - Barron's
UniQure Insists Huntington’s Drug Is Still on Track as Stock Plunges 36% Barron's
Pharma stock soars 150% on injectables deal with Wegovy maker Novo - CNBC
Pharma stock soars 150% on injectables deal with Wegovy maker Novo CNBC
Uniqure Dives 37% On Another Shock For Its Gene Therapy - Investor's Business Daily
Uniqure Dives 37% On Another Shock For Its Gene Therapy Investor's Business Daily
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock. - The Motley Fool
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock. The Motley Fool
MRNA Stock Eyes Best Year Ever: Analyst Calls China’s AI Drug Lead ‘Baseless’ As Moderna Awaits Cancer Data - Yahoo Finance
MRNA Stock Eyes Best Year Ever: Analyst Calls China’s AI Drug Lead ‘Baseless’ As Moderna Awaits Cancer Data Yahoo Finance
Novo shares slide as drugmaker lays out post-Wegovy growth strategy - CNBC
Novo shares slide as drugmaker lays out post-Wegovy growth strategy CNBC
Kodiak Stock Gains 183% as New Eye Drugs Take Aim at Regeneron’s Eylea - Barron's
Kodiak Stock Gains 183% as New Eye Drugs Take Aim at Regeneron’s Eylea Barron's
Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall? - Yahoo Finance
Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall? Yahoo Finance
Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program - Barron's
Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program Barron's
Cigna Stock: Specialty Drug Growth Takes Focus at Investor Day - Barron's
Cigna Stock: Specialty Drug Growth Takes Focus at Investor Day Barron's